Genzyme Enters Oncology Market Via $1 Bil. Acquisition Of Ilex
Executive Summary
Genzyme will pay $1 bil. for its first marketed oncology therapeutic agent through the acquisition of Ilex Oncology
You may also be interested in...
Genzyme Closes Ilex Deal After FTC Orders “Creative” Campath Divestiture
Genzyme will be precluded from any involvement with Campath (alemtuzumab) in the organ transplant rejection therapy market under a consent order with the Federal Trade Commission allowing the company to complete the acquisition of Ilex
Genzyme Closes Ilex Deal After FTC Orders “Creative” Campath Divestiture
Genzyme will be precluded from any involvement with Campath (alemtuzumab) in the organ transplant rejection therapy market under a consent order with the Federal Trade Commission allowing the company to complete the acquisition of Ilex
Campath, Vidaza Payments Raised In OPPS Rule; Zevalin, Bexxar Unchanged
Ilex' Campath (alemtuzumab) will receive enhanced reimbursement in the hospital outpatient setting under the final 2005 OPPS rule